Talcum Powder Mesothelioma Lawsuit Filed Against Multiple Cosmetic Companies
Lawsuit claims numerous talcum powder products used during a Massachusetts woman's life exposed her to asbestos, resulting in a mesothelioma diagnosis in March 2023
Lawsuit claims numerous talcum powder products used during a Massachusetts woman's life exposed her to asbestos, resulting in a mesothelioma diagnosis in March 2023
Asbestos risks in older federal buildings makes it difficult to sell them and recoup taxpayer money spent on cleanup and maintenance, officials say.
Jury was deadlocked in the first trial over the talcum powder ovarian cancer side effects to be held since a stay was lifted when Johnson & Johnson's bankruptcy bids were rejected by the federal court system.
Mesothelioma cancer patients given pegargiminase had a 29% lower risk of death and 35% lower risk of disease progression in a recent clinical study.
Researchers are calling for a total ban on asbestos products around the world, indicating techniques designed to keep workers safe often do not work.
Multi-plaintiff lawsuit originally filed in Pennsylvania state court was improperly removed by Johnson & Johnson, according to a motion brought on behalf of dozens of women who developed ovarian cancer from talcum powder.
Talcum powder settlements were reached last month to resolve two mesothelioma lawsuits, which were prepared to go to trial involving allegations that asbestos in baby powder caused cancer.
One of the talcum powder settlements involved a lawsuit that first went to trial in 2020, but ended in a mistrial after the plaintiff died of mesothelioma complications.
As progress gets underway again to prepare the talcum powder lawsuits for trial, Johnson & Johnson reports it is now considering a third bankruptcy filing, despite federal judges rejecting its two prior efforts.
Over the past two years, plaintiffs have been barred from filing new talcum powder lawsuits, as Johnson & Johnson repeatedly attempted to force the litigation through the U.S. bankruptcy system.